These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12849209)

  • 1. Immunotherapy for Alzheimer's disease.
    Dodel RC; Hampel H; Du Y
    Lancet Neurol; 2003 Apr; 2(4):215-20. PubMed ID: 12849209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological approaches as therapy for Alzheimer's disease.
    Solomon B
    Expert Opin Biol Ther; 2002 Dec; 2(8):907-17. PubMed ID: 12517269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives].
    Karkos J
    Fortschr Neurol Psychiatr; 2004 Apr; 72(4):204-19. PubMed ID: 15095177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance.
    Wang YJ; Zhou HD; Zhou XF
    J Alzheimers Dis; 2010; 21(4):1065-75. PubMed ID: 21504118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
    Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice.
    Zhang Y; Zou J; Yang J; Yao Z
    Curr Alzheimer Res; 2015; 12(4):384-97. PubMed ID: 25817256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease and immunotherapy.
    Solomon B
    Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.
    Rosset MB; Lui G; Dansokho C; Chaigneau T; Dorothée G
    J Neuroinflammation; 2015 May; 12():95. PubMed ID: 25982697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.